PARIS -- The head of France's anti-doping agency is ready to collaborate fully with a U.S. federal investigation into seven-time Tour de France champion Lance Armstrong.
Pierre Bordry said Thursday he will hand over Armstrong's "B" samples from the 1999 Tour to Jeff Novitzky if the Food and Drug Administration agent makes an official request.
French sports daily L'Equipe reported in 2005 that Armstrong's backup samples from 1999 contained EPO -- a banned blood-boosting hormone. Armstrong was cleared by an independent panel.
Novitzky and a federal prosecutor have been handling an inquiry into allegations of organized doping in professional cycling, including whether Armstrong and members of his United States Postal Service team may have been involved. Six of Armstrong's record seven Tour wins came with the team.
Speaking at a news conference about drug testing in France, Bordry said he is impressed by the work done by Novitzky and the U.S. Anti-Doping Agency in Armstrong's case.
"They can ask us anything, we will do it," Bordry said. "We can either send them the samples or do the testing ourselves."
After Armstrong announced his comeback to competition two years ago, Bordry offered him the chance to retest his urine samples from the 1999 Tour in order to quash the doping allegations but the American rejected the offer.
Armstrong's attorney, Mark Fabiani, said the issue of the 1999 samples is "more old news, in an inquiry that is already chock full of stale news."
"This matter was fully investigated by an independent expert starting in 2005, who delivered a 130-page report in 2006, accompanied by hundreds of pages of exhibits, that completely vindicated Armstrong," Fabiani said in a statement.
There was no reliable test for EPO in 1999, but urine samples were preserved and analyzed later when the technology was available.
Bordry said he was not allowed to order a retest of the samples because of the eight-year statute of limitations in the World Anti-Doping Agency code.
Bordry, however, said U.S. federal prosecutors wouldn't be subject to this rule as they are not working on a disciplinary case.
Armstrong has always denied he used performance-enhancing drugs during his record Tour wins from 1999 from 2005. He capped his return to competition with a third-place finish in the 2009 race and competed in what he said was his last Tour in July.
Armstrong, who faced doping accusations since his first Tour win after beating testicular cancer, became a central figure in the federal probe after former teammate Floyd Landis admitted he had doped and alleged that Armstrong and others on his team used banned drugs.
Landis won the Tour in 2006 but was stripped of his title for doping. He dropped years of denials this spring, admitted using performance-enhancing drugs and accused others of doing the same.
Separately, the Los Angeles Times reported that federal prosecutors have obtained a recording of a conversation that former Tour winner and Armstrong critic Greg LeMond secretly taped six years ago with a friend of the cyclist, Stephanie McIlvain.
In it, LeMond asks McIlvain if she would be willing to testify in a lawsuit about what she heard during a disputed 1996 exchange between Armstrong and his doctors about whether he had taken performance-enhancing drugs -- a former teammate and his wife claim Armstrong admitted to taking drugs but the cyclist denies that.
McIlvain tells LeMond on tape she would tell the truth if subpoenaed. Later, in a 2005 civil case, McIlvain denied ever hearing Armstrong admit to drug use. Unauthorized versions of the LeMond-McIlvain conversation have long been available on various cycling websites.
The New York Times, citing anonymous sources, said McIlvain -- who served as the liaison between Armstrong and his sunglasses sponsor, Oakley -- is expected to testify as soon as next week before a grand jury in Los Angeles hearing evidence in the U.S. cycling probe.
McIlvain's attorney, Thomas Bienert Jr., did not immediately return a message seeking comment. No one answered McIlvain's phone.